Madrigal Pharmaceuticals, Inc. MDGL Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $311.34M+127% | $321.08M+211% | $287.27M+362% | $212.8M+1,354% | $137.25M— | ||
| —— | —— | —— | —— | —— | ||
| $108.69M+146% | $116.27M+353% | $174M+153% | $54.08M-23.9% | $44.17M-38.0% | ||
| $268.52M+60.0% | $239.98M+69.9% | $209.12M+94.4% | $196.86M+86.7% | $167.88M+108% | ||
| $404.06M+86.6% | $380.69M+124% | $401.24M+125% | $260M+46.7% | $216.56M+42.4% | ||
| $404.06M+86.6% | $380.69M+124% | $401.24M+125% | $260M+46.7% | $216.56M+42.4% | ||
| $26.85M+495% | $24.45M-96.4% | $18.12M+742% | $9.07M+1,325% | $4.51M— | ||
| -$92.72M-16.9% | -$59.61M+11.0% | -$113.98M+2.0% | -$47.2M+71.0% | -$79.31M+47.8% | ||
| -29.8%+28.0pp | -18.6%+46.3pp | -39.7%+147pp | -22.2%+1,088pp | -57.8%— | ||
| $7.82M+137% | $8.3M+137% | $7.45M+103% | $3.26M-10.7% | $3.3M-14.1% | ||
| $8.24M-12.0% | $9.46M-14.6% | $10.31M-20.8% | $8.23M-42.2% | $9.37M+12.4% | ||
| -$2.09M— | -$128K— | -$293K— | -$42K— | $0— | ||
| -$94.39M-28.9% | -$58.58M+1.4% | -$114.19M-6.8% | -$42.28M+72.2% | -$73.24M+50.4% | ||
| -30.3%+23.0pp | -18.2%+39.3pp | -39.8%+132pp | -19.9%+1,018pp | -53.4%— | ||
| -$3.25-24.5% | -$2.03— | -$4.01+18.5% | -$1.50+78.9% | -$2.61+64.6% | ||
| -$3.25-24.5% | -$2.03— | -$4.01+18.5% | -$1.50+78.9% | -$2.61+64.6% | ||
| 29M+3.4% | 28.4M+5.6% | 28.5M+31.1% | 28.2M+31.9% | 28.1M+40.4% | ||
| 29M+3.4% | 28.4M+5.6% | 28.5M+31.1% | 28.2M+31.9% | 28.1M+40.4% | ||
| -$2.09M— | -$128K— | -$293K— | -$42K— | $0— | ||
| $108.69M+146% | $116.27M+353% | $174M+153% | $54.08M-23.9% | $44.17M-38.0% | ||
| $311.34M+127% | $321.08M+211% | $287.27M+362% | $212.8M+1,354% | $137.25M— | ||
| -$92.72M-16.9% | -$59.61M+11.0% | -$113.98M+2.0% | -$47.2M+71.0% | -$79.31M+47.8% | ||
| -$92.34M-17.0% | -$59.22M+11.1% | -$113.62M+2.1% | -$46.83M+71.1% | -$78.93M+48.0% | ||
| -$92.34M-17.0% | -$59.22M+11.1% | -$113.62M+2.1% | -$46.83M+71.1% | -$78.93M+48.0% | ||
| -29.7%+27.9pp | -18.4%+46.0pp | -39.6%+147pp | -22%+1,087pp | -57.5%— | ||
| -$92.72M-16.9% | -$59.61M+11.0% | -$113.98M+2.0% | -$47.2M+71.0% | -$79.31M+47.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s revenue?
- Madrigal Pharmaceuticals, Inc. (MDGL) generated $1.1B in revenue over the trailing twelve months, up 256.8% year over year.
- Is Madrigal Pharmaceuticals, Inc. profitable?
- Madrigal Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $309.4M over the trailing twelve months, a -27.3% net margin.
- What are Madrigal Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 96.5% and operating margin is -27.7%, with a -27.3% net margin.
- What is Madrigal Pharmaceuticals, Inc.'s earnings per share?
- Madrigal Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-10.79.
- Where does Madrigal Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
